Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2022 | The central vein sign: a novel imaging biomarker for MS diagnosis

Pascal Sati • 26 Feb 2022
ACTRIMS 2022
Multiple Sclerosis and Related Disorders

Pascal Sati, PhD, Cedars-Sinai Medical Center, Los Angeles, CA, talks on the central vein sign (CVS) as a novel imaging biomarker for diagnosing multiple sclerosis (MS). The CVS is a signature of inflammatory demyelinated lesions within the brain and is a frequent finding in MS, distinguishing MS cases from non-MS. Various criteria are currently being explored based on the proportion and number of CVS lesions for the accurate differentiation of MS versus non-MS. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.

More from Pascal Sati

Validating biomarkers in MS for clinical practice – a large prospective cohort
2:19
Validating biomarkers in MS for clinical practice – a large prospective cohort
Pascal Sati • 26 Feb 2022
Diagnostic potential of paramagnetic rim lesions in MS
1:53
Diagnostic potential of paramagnetic rim lesions in MS
Pascal Sati • 26 Feb 2022
Translating MS imaging biomarkers into clinical practice
1:41
Translating MS imaging biomarkers into clinical practice
Pascal Sati • 26 Feb 2022
MS-ReBS: combining visual, radiological, and blood biomarkers for disability prediction in MS
1:39
MS-ReBS: combining visual, radiological, and blood biomarkers for disability prediction in MS
Pascal Sati • 26 Feb 2022

Related Videos

What are the key changes introduced in the 2024 revision of the McDonald diagnostic criteria for MS?
6:48
What are the key changes introduced in the 2024 revision of the McDonald diagnostic criteria for MS?
Mar Tintoré • 3 Jul 2026
Ovarian aging and long-term prognosis in women with multiple sclerosis
3:07
Ovarian aging and long-term prognosis in women with multiple sclerosis
Mar Tintoré • 3 Jul 2026
The emerging role of AI in the diagnosis and management of multiple sclerosis
1:55
The emerging role of AI in the diagnosis and management of multiple sclerosis
Celia Oreja-Guevara • 29 Jun 2026
Can selected patients with multiple sclerosis safely discontinue ocrelizumab?
3:15
Can selected patients with multiple sclerosis safely discontinue ocrelizumab?
Franz Felix Konen • 28 Jul 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals